Search Within

Claire Frances Friedman

Formats
  1. Meeting Abstract (60)
  2. Journal Article (55)
  3. Editorial (2)
  4. Book Section (1)
  5. Guidelines (1)
  6. Research Letter (1)
  7. Review (1)
Groups
  1. Department of Medicine (121)
  2. GDMT, Medicine (121)
  3. Gynecologic Medicine Service (121)
  4. Gynecology Disease Management Team (121)
  5. Solid Tumor Oncology Division (121)
  6. Weinberg Fellows (121)

More Groups

People
  1. Carol Aghajanian (44)
  2. Dmitriy Zamarin (41)
  3. Britta Weigelt (32)
  4. Roisin O'Cearbhaill (30)
  5. Nadeem Abu-Rustum (27)
  6. Vicky Makker (26)

More People

Years
  1. 2025 (9)
  2. 2024 (19)
  3. 2023 (11)
  4. 2022 (29)
  5. 2021 (12)
  6. 2020 (16)

More Years

Publications
  1. Journal of Clinical Oncology (26)
  2. Gynecologic Oncology (18)
  3. Annals of Oncology (11)
  4. International Journal of Gynecological Cancer (10)
  5. Journal for ImmunoTherapy of Cancer (10)
  6. Clinical Cancer Research (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (27)
  2. Elsevier B.V. (23)
  3. American Association for Cancer Research (15)
  4. Oxford University Press (14)
  5. Biomed Central Ltd (10)
  6. Lippincott Williams & Wilkins (10)

More Publishers

Results (121)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • MyPathway: A multiple target, multiple basket study of targeted treatments in tissue-agnostic cohorts of patients (pts) with advanced solid tumors
    Meeting Abstract

    Friedman, C.; Swanton, C.; Spigel, D.; Bose, R.; Burris, H.; Yu, W.; Wang, Y.; Malato, J.; Price, R.; Darbonne, W.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Ovarian cancer mutational processes drive site-specific immune evasion
    Journal Article

    Vázquez-García, I.; Uhlitz, F.; Ceglia, N.; Lim, J. L. P.; Wu, M.; Mohibullah, N.; Niyazov, J.; Ruiz, A. E. B.; Boehm, K. M.; Bojilova, V.; more...
    Nature (2022)

    Fulltext@MSK | Save
  • Gastric-type adenocarcinoma of the cervix: Clinical outcomes and genomic drivers
    Journal Article

    Ehmann, S.; Sassine, D.; Straubhar, A. M.; Praiss, A. M.; Aghajanian, C.; Alektiar, K. M.; Broach, V.; Cadoo, K. A.; Jewell, E. L.; Boroujeni, A. M.; more...
    Gynecologic Oncology (2022)

    Fulltext@MSK | Save
  • Bifunctional blockade: A novel immunotherapy approach for cervical cancer
    Editorial

    Miller, K. M.; Friedman, C. F.
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Cell-free DNA analysis as a molecular tool to monitor response to immune checkpoint inhibition in endometrial cancer
    Meeting Abstract

    Manning-Geist, B.; Patel, J. A. A.; Marra, A.; Da Cruz Paula, A.; Hanlon, E. J.; Abu-Rustum, N.; Shah, R. H.; Berger, M. F.; Hensley, M. L.; Zamarin, D.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development
    Meeting Abstract

    Liu, D.; Murciano-Goroff, Y. R.; Jee, J.; Arcila, M. E.; Buonocore, D. J.; Gao, J.; Chakravarty, D.; Schram, A. M.; Callahan, M. K.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase 1 study of SGN-ALPV, a novel, investigational vedotin antibody-drug conjugate directed to ALPP/ALPPL2 in advanced solid tumors (SGNALPV-001, trial in progress)
    Meeting Abstract

    Lakhani, N. J.; Friedman, C. F.; Perez, C. A.; Wehr, A.; McGoldrick, S. M.; LoRusso, P.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A phase II trial of IDO-inhibitor, BMS-986205 (IDO), and PD-1 inhibitor, nivolumab (NIVO), in recurrent or persistent endometrial cancer (EC; CA017-056)
    Meeting Abstract

    Kyi, C.; Rubinstein, M. M.; Shah, P.; Zhou, Q.; Iasonos, A.; Liu, Y.; Ramirez, L.; Paroder, V.; Green, A.; Friedman, C. F.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Basket study of oral progesterone antagonist onapristone extended release (ONA-XR) in progesterone receptor positive (PR+) recurrent granulosa cell (GCT), low-grade serous ovarian (LGSOC), or endometrioid endometrial cancer (EEC)
    Meeting Abstract

    Grisham, R. N.; Li, K.; Zhou, Q.; Iasonos, A.; Girshman, J.; Shah, P.; Jang, D.; Kyi, C.; Cohen, S. M.; O'Cearbhaill, R. E.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Dysfunctional CD8+T cells in the tumor microenvironment are associated with response to nivolumab in mismatch repair deficient (dMMR) or hypermutated ovarian (OVCA) or endometrial cancer (EC)
    Meeting Abstract

    Friedman, C. F.; Zhou, Q.; Iasonos, A.; Holland, A.; Ramirez, L.; Grisham, R. N.; Guo, R.; Lichtman, S. M.; Kyi, C.; Makker, V.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save